Abstract:Dipeptidyl peptidase-4 inhibitors（DPP-4i）have demonstrated stable hypoglycemic efficacy in the treatment of type 2diabetes mellitus（T2DM），with a generally low risk of hypoglycemia. Long-term studies also suggest that they have favorable evidence for cardiovascular and renal safety，and their impact on body weight is largely neutral. Based on these advantages，DPP-4i are increasingly used in primary medical and healthcare institutions. Several guidelines recommend DPP-4i as one of the first-line glucose-lowering drugs for elderly patients with T2DM. This recommendation is intended to provide concise，question-and-answer-style guidance on common issues in the clinical application of DPP-4i for physicians in primary medical and healthcare institutions. Thegoal is to standardize medication use，improve treatment safety and efficacy，and thereby better enhance patient outcomes.